分子診斷合作與授權協議（2016-2025）

本報告全面深入分析了全球領先的生物製藥公司簽署的分子診斷合作與許可協議，讓您能夠以前所未有的方式了解這些協議。

本報告經過全面修訂和更新，詳細介紹了2016年至2025年間的分子診斷協議。

本報告深入分析了企業簽訂分子診斷協議的原因和方式。這些協議通常包含多個組成部分，從合作研發開始，逐步推進到成果的商業化。

本報告涵蓋合作、開發、研究和授權等內容。

本報告包​​含自2016年以來公佈的759項分子診斷協議的完整清單，其中包括可用的財務條款以及合約雙方披露的實際分子診斷合作協議的線上記錄連結。此外，在條件允許的情況下，記錄還包括公司及其合作夥伴向美國證券交易委員會提交的合約文件。

本報告第一章概述了分子診斷領域的交易活動。

第一章概述了本報告。

第二章概述了自2016年以來分子診斷領域的交易活動。

第三章概述了自2016年以來主要的分子診斷交易，並依交易總額列出。

第四章提供了分子診斷領域交易活動最活躍的前25家公司的完整列表，並附有簡要概述，以及分子診斷交易和公開合約文件的完整列表。

第五章對自2016年1月以來已完成或宣布的、有公開合約文件的分子診斷相關交易進行了全面深入的審查。

第六章對自2016年1月以來簽署和公佈的分子診斷合作協議進行了全面深入的回顧。本章以具體的分子診斷技術類型進行組織。

本報告也包含大量表格和圖表，展示了自2016年以來分子診斷領域的交易趨勢和活動。

此外，我們還提供了一個全面的協議目錄，依公司名稱（A-Z）、協議類型和治療靶點進行分類。每個協議標題都透過網路連結指向線上協議記錄，並在可用的情況下指向協議文件，方便用戶根據需要輕鬆存取每個協議文件。

主要優勢

"分子診斷合作與授權協議" 報告提供讀者以下主要優勢：

• 了解2016年以來的交易趨勢
• 瀏覽分子診斷領域的合作與授權協議
• 基準分析 - 確定交易市場價值
• 財務條款 - 首付款、里程碑付款、特許權使用費
• 依公司（A-Z）、協議類型和治療領域分類的合約目錄
• 以價值排名的主要交易
• 最活躍的交易撮合者
• 識別每筆交易中的資產和合約條款
• 存取合約文件 - 深入了解交易結構
• 盡職調查 - 評估擬議交易條款對合作公司的適用性
• 節省數百小時的研究時間

範圍

• "分子診斷合作與許可協議報告" 旨在幫助讀者深入了解分子診斷的發展趨勢以及全球主要生物製藥公司正在簽訂的協議結構。

分子診斷合作與授權協議包括：

• 生物製藥產業的分子診斷交易趨勢
• 製藥和生物技術公司分子診斷合約記錄目錄
• 依價值劃分的主要分子診斷交易
• 最活躍的分子診斷許可協議
• 分子診斷合作與許可協議提供對現有交易記錄的全面訪問，包括合約文件（如有）。

分析合約有助於對以下內容進行盡職調查：

• 合約中具體授予或選擇哪些權利？
• 合約實際上賦予合作夥伴哪些權利？
• 授予了哪些獨家經營權？
• 交易的付款結構是怎麼樣的？
• 銷售和付款如何審計？
• 合約期限是多久？
• 合約的關鍵條款是如何定義的？
• 知識產權（IPR）如何處理與歸屬？
• 誰負責商業化？
• 誰負責開發、供應和生產？
• 如何管理保密性和資訊揭露？
• 如何解決爭議？
• 在什麼情況下可以終止合約？
• 如果所有權發生變更，會發生什麼事？
• 如何約定轉讓許可和分包條款？
• 貴公司要求哪些標準條款？
• 哪些標準條款會因交易對手和交易類型而異？
• 貴公司必須受哪個司法管轄區管轄？

目錄

摘要整理

第一章：引言

第二章：分子診斷交易趨勢

• 引言
• 歷年分子診斷交易
• 最活躍的分子診斷經銷商
• 以交易類型劃分的分子診斷交易
• 依治療領域劃分的分子診斷交易
• 依行業劃分的分子診斷交易
• 分子診斷交易條款
  • 分子診斷交易的關鍵價值策略
  • 分子診斷合約預付款
  • 分子診斷交易里程碑付款
  • 分子診斷特許權使用費率

章節第三章：分子診斷領域的關鍵交易

• 引言
• 頂級分子診斷交易價值策略

第四章：最活躍的分子診斷交易撮合者

• 引言
• 最活躍的分子診斷經銷商
• 最活躍的分子診斷交易公司簡介

第五章：分子診斷交易目錄

• 引言
• 分子診斷交易目錄

第六章：依技術類型劃分的分子診斷交易

• 交易目錄
• 依公司劃分的分子診斷交易目錄（亞利桑那州）
• 以交易類型劃分的分子診斷交易目錄
• 依分子診斷交易類型劃分的交易目錄依治療領域劃分的診斷交易
• 交易類型定義
• 關於研究公司
• 當前合作夥伴
• 當前協議
• 近期合作夥伴報告標題

Molecular Diagnostics Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the molecular diagnostics deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of molecular diagnostics deals from 2016 to 2025.

The report provides a detailed understanding and analysis of how and why companies enter molecular diagnostics deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 759 molecular diagnostics deals announced since 2016 including financial terms where available including links to online deal records of actual molecular diagnostics partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of molecular diagnostics dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in molecular diagnostics dealmaking since 2016.

Chapter 3 provides an overview of the leading molecular diagnostics deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in molecular diagnostics dealmaking with a brief summary followed by a comprehensive listing of molecular diagnostics deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of molecular diagnostics deals signed and announced since Jan 2016, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of molecular diagnostics partnering deals signed and announced since Jan 2016. The chapter is organized by specific molecular diagnostics technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in molecular diagnostics deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Molecular Diagnostics Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse molecular diagnostics collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Molecular Diagnostics Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of molecular diagnostics trends and structure of deals entered into by leading biopharma companies worldwide.

Molecular Diagnostics Collaboration and Licensing Deals includes:

• Trends in molecular diagnostics dealmaking in the biopharma industry
• Directory of molecular diagnostics deal records covering pharmaceutical and biotechnology
• The leading molecular diagnostics deals by value
• Most active molecular diagnostics licensing dealmakers
• Molecular Diagnostics Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in molecular diagnostics dealmaking

• 2.1. Introduction
• 2.2. Molecular diagnostics deals over the years
• 2.3. Most active molecular diagnostics dealmakers
• 2.4. Molecular diagnostics deals by deal type
• 2.5. Molecular diagnostics deals by therapy area
• 2.6. Molecular diagnostics deals by industry sector
• 2.7. Deal terms for molecular diagnostics deals
  • 2.7.1 Molecular diagnostics deals headline values
  • 2.7.2 Molecular diagnostics deal upfront payments
  • 2.7.3 Molecular diagnostics deal milestone payments
  • 2.7.4 Molecular diagnostics royalty rates

Chapter 3 - Leading molecular diagnostics deals

• 3.1. Introduction
• 3.2. Top molecular diagnostics deals by value

Chapter 4 - Most active molecular diagnostics dealmakers

• 4.1. Introduction
• 4.2. Most active molecular diagnostics dealmakers
• 4.3. Most active molecular diagnostics deals company profiles

Chapter 5 - Molecular diagnostics contracts dealmaking directory

• 5.1. Introduction
• 5.2. Molecular diagnostics contracts dealmaking directory

Chapter 6 - Molecular diagnostics dealmaking by technology type

• Deal directory
• Deal directory - Molecular diagnostics deals by company A-Z
• Deal directory - Molecular diagnostics deals by deal type
• Deal directory - Molecular diagnostics deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Molecular diagnostics deals since 2016
• Figure 2: Active molecular diagnostics dealmaking activity - 2016 - 2025
• Figure 3: Molecular diagnostics deals by deal type since 2016
• Figure 4: Molecular diagnostics deals by therapy area since 2016
• Figure 5: Molecular diagnostics deals by industry sector since 2016
• Figure 6: Molecular diagnostics deals with a headline value
• Figure 7: Molecular diagnostics deals with an upfront value
• Figure 8: Molecular diagnostics deals with a milestone value
• Figure 9: Molecular diagnostics deals with a royalty rate value
• Figure 10: Top molecular diagnostics deals by value since 2016
• Figure 11: Most active molecular diagnostics dealmakers 2016 - 2025
• Figure 12: Molecular diagnostics deals by technology type since 2016